The genuinely unsettled questions in clinical cardiology, ranked by debate-worthiness. Scanned continuously from the major journals, FDA actions, new guidelines, and the conversation among cardiologists on X.
10 live debatesLast scanned Aug 18, 2026, 8:40 AM UTC
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
How much practice changes9.0 · 30%
How much is genuinely new6.7 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.9 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Values & turf — what this means
A trade-off or turf question that more data alone won't settle — it turns on risk tolerance, cost, or which specialty owns the decision.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (2 vs 2 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (16 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jan 2025).
On the boardhow long the question has been live on Synapse (7 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
01★ Top debate
One BP target for all, or tailor it?
2025 AHA/ACC hypertension guideline: lower thresholds or individualized targets?
How you read the new guideline decides whether every hypertensive patient gets pushed to under 130/80, or whether frail and elderly patients get looser goals to avoid falls, kidney injury, and overtreatment.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.3 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.3 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.0 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.3 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.5 · 40%
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
Debates are surfaced by a continuous scan of the cardiology literature and the conversation among clinicians. The heat score (0-10) reflects how live and consequential the disagreement is right now and drives the ranking; it becomes the measured expert split as cardiologists weigh in. Quotes and engagement counts are scan-reported and link to their primary source.
Millions of patients
Outlook: A judgment call — more data alone won't fully settle it
For adults with confirmed hypertension under the 2025 guideline, should clinicians drive all patients toward <130/80, or set individualized targets by frailty and risk?
Push everyone to <130/80
A single low, clear target is easy to act on and drives down strokes and heart attacks across the whole population, where undertreatment is the bigger real-world problem.
“Based on these, the 2025 American College of Cardiology/American Heart Association guideline recommends in adults with confirmed hypertension, an office blood pressure goal of <130/80 mm Hg, with encouragement to further reduce systolic blood pressure to <120 mm Hg. Here, we set ”
Lucas Lauder · Cardiologist; co-author of debate article supporting 2025 guideline targets · Hypertension ↗
“Based on these, the 2025 American College of Cardiology/American Heart Association guideline recommends in adults with confirmed hypertension, an office blood pressure goal of <130/80 mm Hg, with encouragement to further reduce systolic blood pressure to <120 mm Hg.”
Felix Mahfoud · Interventional cardiologist; co-author of debate article supporting lower targets · Hypertension ↗
Tailor the target to the patient
A rigid low goal risks harming the old, frail, and multimorbid, so targets should flex to individual risk and tolerance rather than one number for all.
“By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure and reduce the toll of heart disease, kidney disease, Type 2 diabetes and dementia.”
On the board:since Jun 24, 2026 (7 weeks)— time live on Synapse
Patients affected:Millions of patients· hypertension is routine across cardiology
›The evidence
What we know
✓The 2025 AHA/ACC guideline sets an office goal of under 130/80.
✓Lower blood pressure reduces cardiovascular events in most adults.
✓The guideline also stresses risk-based, earlier, and team-based management.
✓Aggressive lowering carries real harms in some patients — falls, kidney injury, dizziness.
What's still unknown
?Whether the same low target truly benefits the very elderly and frail.
?How to identify which patients are helped versus harmed by intensive lowering.
?Long-term outcomes of applying one target across all risk levels in routine practice.
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
How much practice changes8.5 · 30%
How much is genuinely new7.9 · 20%
Clinician attention8.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.9 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 78%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (3 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (26 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Aug 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
02Field-wide debate
Continuing beta-blockers long-term after uncomplicated MI
Get this wrong and millions of stable post-MI patients either swallow a daily pill for nothing or lose real arrhythmia and remodeling protection.
In revascularized post-MI patients with preserved EF on modern guideline therapy, should clinicians routinely stop the beta-blocker or continue it indefinitely?
Stop the beta-blocker
Modern trials in patients with preserved EF show no survival or event benefit, so continuing only adds side effects, fatigue, and pill burden with nothing to gain.
“Beta-blockers have long been a foundational treatment after acute MI; however, supporting evidence is derived from trials that predate modern standards of care − before the time of routine reperfusion, invasive management, potent antiplatelet therapies and statins. Re-examining t”
“Based on the REDUCE-AMI trial results, I would recommend that routine beta-blockers for patients like those included in that trial (revascularized 1- or 2-vessel disease and LVEF ≥50%) is no longer necessary.”
How much practice changes8.0 · 30%
How much is genuinely new8.3 · 20%
Clinician attention8.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.7 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 86%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (0 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (26 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jun 2020).
On the boardhow long the question has been live on Synapse (8 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
03Field-wide debate
Watchman FLX as first-line vs NOACs in eligible AF patients?
Get this wrong and a generation of stroke-eligible AF patients trades a daily pill they could safely take for a permanent implant that may leave them more prone to stroke.
In AF patients fully eligible for long-term anticoagulation, should left atrial appendage closure be offered as a first-line alternative to NOACs given a noninferior composite but a higher ischemic stroke signal?
Offer the device early
Trials met noninferiority for the hard composite while cutting serious nonprocedural bleeding, so patients who hate or fear lifelong anticoagulation finally have a real alternative without waiting to fail pills first.
Keep pills first-line
The numerically higher ischemic stroke signal, soft composite endpoints, and industry funding mean we can't yet call a one-time implant equal to a proven drug we can stop if something goes wrong.
“I’m not convinced that these devices should be considered an equal substitute for NOACs.”
Weighted (40 / 30 / 20 / 10) into the 8.6 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Coordination gap — what this means
The answer is roughly known, but everyday practice and guidelines lag behind the evidence. The fight is about adoption, not the science.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (5 vs 2 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (18 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2019).
On the boardhow long the question has been live on Synapse (7 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
04Field-wide debate
Drop aspirin early after a heart attack?
Shorter DAPT or earlier aspirin withdrawal after ACS?
Cut aspirin too soon and high-risk patients throw clots; keep it too long and they bleed — this decides the default regimen for nearly everyone leaving the cath lab after ACS.
Outlook: Evidence is largely in — the gap now is putting it into practice
In post-ACS patients on dual antiplatelet therapy, should aspirin be withdrawn at 1-3 months in favor of P2Y12 monotherapy, or should the standard 12-month regimen continue until powered trials identify who can safely de-escalate?
De-escalate early
Pulling aspirin at 1-3 months and running P2Y12 monotherapy cuts bleeding without a clear ischemic penalty, so the old 12-month dual regimen overtreats most patients.
“antiplatelet and anticoagulation trials test earlier withdrawal of aspirin or oral anticoagulants to reduce bleeding risk”
“test earlier withdrawal of aspirin or oral anticoagulants to reduce bleeding risk and simplify treatment”
Professor Tomasz Guzik ·
How much practice changes7.5 · 30%
How much is genuinely new6.9 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.9 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (5 vs 2 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (13 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Feb 2026).
On the boardhow long the question has been live on Synapse (8 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
05Field-wide debate
Bust the clot or just anticoagulate in submassive PE?
Thrombolysis or anticoagulation alone for intermediate-risk PE?
Resolve this and you decide whether thousands of stable PE patients with a strained right ventricle get an invasive clot-busting procedure with bleeding risk, or just blood thinners and watchful waiting.
For intermediate-to-high-risk PE with RV strain and positive troponin but stable hemodynamics, should clinicians use early catheter-directed thrombolysis or reserve it and start with anticoagulation alone?
Intervene early
Catheter-directed thrombolysis unloads the strained right ventricle faster and may cut the chance a stable patient suddenly crashes, instead of waiting for deterioration that's hard to reverse.
“ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation led to a lower risk”
“61% lower risk of decompensation and other hard outcomes at 7 days”
Stavros V. Konstantinides ·
How much practice changes8.0 · 30%
How much is genuinely new8.2 · 20%
Clinician attention7.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.3 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 97%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (13 vs 0 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (24 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jul 2022).
On the boardhow long the question has been live on Synapse (7 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
06Field-wide debate
Treat high Lp(a) now, or wait for the trials?
Should we measure and treat elevated Lp(a) now or wait for phase 3 outcomes?
Whether we start measuring Lp(a) in everyone and acting on it today, or hold off until 2026 trials tell us if lowering it actually prevents heart attacks.
In patients found to have elevated Lp(a), should we screen broadly and act now — or defer routine measurement and any Lp(a)-targeted treatment until the 2026 outcomes trials report?
Screen and act now
Lp(a) is genetic, lifelong, and identifies high-risk patients we can already help — measure it now and intensify everything else we know works while waiting for the targeted drugs.
“Novel therapeutic approaches show promise for targeted reduction of Lp(a)”
“We want clinicians to start assessing Lp(a) now so that when Lp(a)-targeted therapies become available, we’ll be ready to treat the patients who need them.”
·
How much practice changes8.5 · 30%
How much is genuinely new6.9 · 20%
Clinician attention8.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Coordination gap — what this means
The answer is roughly known, but everyday practice and guidelines lag behind the evidence. The fight is about adoption, not the science.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (2 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (10 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2024).
On the boardhow long the question has been live on Synapse (8 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
07Field-wide debate
New AF ablation tech: worth it if efficacy ties?
PFA vs thermal ablation for AF: does it change long-term outcomes?
If pulsed field ablation only matches radiofrequency on keeping AF away, cath labs are switching to a pricier tool for speed and safety alone — and paying for it across nearly every AF ablation.
Outlook: Evidence is largely in — the gap now is putting it into practice
In paroxysmal AF ablation, when PFA and RF show comparable efficacy, should PFA's safety and speed advantages justify switching from RF as the default?
Adopt PFA now
Even with equal efficacy, PFA spares the esophagus, phrenic nerve, and other collateral tissue and runs faster, so the safety and workflow gains justify the switch.
“Taken together, these data demonstrate that the favorable outcomes of PFA are maintained over the course of 4 years. Coupled with the safety advantages of PFA over thermal ablation, these long-term data support widespread adoption of PFA for the treatment of AF.”
“Both PFA and RFA using the CLOSE protocol showed excellent and similar efficacy. Single-procedure success rates were comparable, although there appeared to be fewer complications and a shorter procedure time with PFA.”
·
How much practice changes8.5 · 30%
How much is genuinely new7.9 · 20%
Clinician attention8.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.6 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (1 vs 0 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (29 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jan 2022).
On the boardhow long the question has been live on Synapse (8 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
08Field-wide debate
TAVR or SAVR for lifetime management in young low-risk aortic stenosis patients?
Pick wrong for a 55-year-old and you either lock them into a TAVR-in-TAVR future nobody has decades of data on, or you put them through open surgery they may not have needed.
For patients under 65 with severe aortic stenosis and current durability data, should the first valve be surgical to protect lifetime options, or transcatheter with a plan to reintervene?
Surgery first
A young patient has decades ahead, and a durable surgical valve preserves the cleanest options for the inevitable reinterventions that lie down the road.
“The SAVR/TAVR decision is a lifetime strategy, not a single episode of care.”
Outcomes match surgery out to several years with faster recovery, and the patient can start with the less invasive option and plan to layer valves later.
Undecided
How much practice changes7.0 · 30%
How much is genuinely new7.9 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Sources — the evidence behind it
How many distinct sources we linked for this debate (10 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Apr 2023).
On the boardhow long the question has been live on Synapse (8 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
09Field-wide debate
Myosin inhibitors for obstructive HCM: first-line or after beta-blockers?
Pick wrong and patients either swallow a costly drug needing constant echo monitoring when cheap beta-blockers would do, or keep getting septal procedures we could have avoided.
In symptomatic obstructive HCM, should myosin inhibitors be used as first-line therapy or reserved until beta-blockers or calcium channel blockers fail, given no mature head-to-head data?
Cheap drugs first
Beta-blockers and verapamil are inexpensive, decades-proven, and safe, so a pricey myosin inhibitor with mandatory echo surveillance should wait until they fail.
Inhibitors earlier
Myosin inhibitors target the actual disease mechanism, relieve obstruction directly, and can spare patients an invasive septal reduction the older drugs never prevent.
Undecided
“Currently, myosin inhibitor therapy is recommended as a second-line treatment for patients with persistent symptoms on beta-blockers. But here we show that aficamten – as monotherapy and as first-line therapy – demonstrated greater improvements in exercise capacity and symptoms t”
Pablo Garcia-Pavia · Principal Investigator · ESC ↗
How much practice changes7.5 · 30%
How much is genuinely new8.2 · 20%
Clinician attention6.9 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.5 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (7 vs 0 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (9 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Nov 2025).
On the boardhow long the question has been live on Synapse (4 weeks).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
10Specialist debate
Drop to blood thinner alone one month after a stent?
One month or 12 months dual antithrombotic therapy after PCI in AF patients?
How quickly you drop the P2Y12 inhibitor decides whether AF stent patients bleed less or clot more — and the answer sets everyday practice for a huge, growing group.
In AF patients undergoing PCI, should dual antithrombotic therapy be stopped at 1 month and converted to blood thinner alone across broader real-world populations, or extended toward 12 months in higher-risk subgroups?
De-escalate at one month
One month of dual therapy prevented ischemic events just as well as a year while causing far less bleeding, so keeping patients on two agents longer just wounds them without protecting them.
“Patients with atrial fibrillation who receive a stent may only need 1 month of dual antithrombotic therapy, instead of 1 year.”
“The marked reduction in the primary bleeding endpoint supports earlier de-escalation in carefully selected patients, particularly those with chronic coronary syndrome, treated with contemporary drug-eluting stents, undergoing intravascular imaging-guided PCI.”
“We're trying to get a clear message to primary care clinicians... to encourage them to be more aggressive in managing blood pressure, to get blood pressure lower.”
Insufficient evidence (1 studies, 0 patients) to determine the effect of lower blood pressure targets (120-140 mmhg) on the outcome in Hypertensive disease.
Supporting
+Does the benefit from treating to lower blood pressure targets vary with age? A systematic review and meta-analysis
Beta-blockers still guard against arrhythmias and adverse remodeling, and the newer trials may miss harder, longer-term events the older data captured.
“Differences between the groups with respect to hospitalisation for cardiovascular reasons and the negative effect on blood pressure levels, together with the absence of quality-of-life improvement do not support interruption of a chronic beta-blocker treatment in post-MI patients”
“REBOOT-CNIC, BETAMI, and DANBLOCK examine whether long-term beta-blockers are still needed in myocardial infarction, especially if heart function remains preserved.”
“examine whether long-term beta-blockers are still needed in myocardial infarction, especially if heart function (ejection fraction) remains preserved”
“REBOOT-CNIC and BETAMI-DANBLOCK examine whether long-term beta-blockers are still needed in myocardial infarction, especially if ejection fraction remains preserved.”
“In appropriately selected patients who survived a heart attack and do not have HF or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary.”
“For this population with AMI and revascularization and preserved LVEF and no other reason to use a beta-blocker (like hypertension or arrhythmias), I no longer prescribe beta-blockers.”
“My read on the totality of the data is that the benefit is mediocre at best when compared with [use in] heart failure with reduced ejection fraction.”
“The message should not be ‘stop beta-blockers after MI,’ but rather ‘consider withdrawal only when the residual ischemic and arrhythmic risk is truly minimal.’”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“If positive, the results of our trial will create a new paradigm of combining mechanical and medical strategies to prevent stroke among patients with AF who are at higher risk of stroke.”
Jeff Healey · Cardiologist/Electrophysiologist · PHRI ↗
“LAA occlusion remained noninferior to DOAC therapy in terms of the primary composite endpoint.”
“I think the result was indeed somewhat unexpected for us, because this is exactly the patient population where we are now doing left atrial appendage closure.”
“We really have to have a good conversation with them. We’ve all seen patients who have a CHA2DS2-VASc score of 0 and then a few months down the road they have a stroke.”
“The Watchman FLX left atrial appendage closure device may be considered as an alternative to NOACs in a shared decision-making process with atrial fibrillation patients who are deemed suitable for long-term oral anticoagulants.”
“Antiplatelet and anticoagulation trials like NEO-MINDSET, TARGET FIRST, DUAL-ACS test earlier withdrawal of aspirin or oral anticoagulants to reduce bleeding risk.”
“Abbreviation of DAPT duration after 1–6 months, followed by monotherapy with aspirin or a P2Y12 inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk.”
“Recent evidence suggests that withdrawal of aspirin after 1 to 3 months of DAPT, followed by P2Y12 inhibitor monotherapy may reduce bleeding while preventing recurrent ischaemic events compared with 12 months of DAPT.”
Until adequately powered trials pin down exactly who can safely drop aspirin, abandoning the guideline-recommended 12 months risks recurrent thrombosis in patients who still need protection.
“In high-risk PCI patients, further ischemic events remain a life-threatening concern. As seen in TWILIGHT, in patients who tolerated three months of dual antiplatelet therapy, lowering the risk of major bleeding while preserving the ischemic benefit using ticagrelor monotherapy i”
“Until adequately powered randomised controlled trials demonstrate a clinically meaningful identification of those patients, we should continue to adhere to the current guideline-recommended 12-month minimum DAPT duration following ACS.”
“We failed to demonstrate the noninferiority of aspirin-free monotherapy initiated immediately after PCI with regard to the ischemic primary endpoint over 12 months.”
“No previous randomized trials have assessed early aspirin discontinuation in acute MI patients who achieve early, complete revascularization with modern stents.”
Named experts we found publicly on record — a sample, not a representative poll of the field.
Where do you land?
No votes yet — the measured split appears at 10.
Estimated patients affected
680K–1.1M
Around 900,000 PCIs are performed every year in the U.S.→The default strategy in patients with ACS who are not at high bleeding risk is DAPT for at least 12 months.
6 studies (71,537 patients) provide insufficient evidence with mixed findings regarding aspirin for the outcome in Acute Coronary Syndrome.
Supporting
+Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis
Dissenting
−Preoperative dual antiplatelet therapy increases risk after urgent coronary bypass surgery: A Netherlands heart registration study
−Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy
−P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis
“The study largely confirms what a lot of people in the PE world have suspected, which is that the use of catheter-based interventions, including catheter-based thrombolysis, improves patient outcomes.”
Most intermediate-risk patients do fine on blood thinners alone, so adding a procedure exposes them to bleeding and cost for a benefit that may only exist in a narrow sicker subset.
“For the majority of patients with intermediate-risk PE, anticoagulation remains the right treatment. For the narrow subset with objective evidence of RV strain, positive troponin, and clinical signs of physiologic stress, CDT now has RCT evidence supporting its use.”
“CDT should be considered for patients with high-risk PE, in whom thrombolysis is contraindicated or has failed. Also, CDT is a treatment option for initially stable patients in whom anticoagulant treatment fails.”
Piotr Pruszczyk · ESC Working Group on Pulmonary Circulation · EuroIntervention ↗
Undecided
“This guideline is a road map to help clinicians navigate these advances for the safest and most effective approaches to care for people with this condition.”
“This trial shows that a catheter intervention can indeed be effective and improve the prognosis for patients with severe PE and elevated risk of early death or life-threatening complications.”
Stavros V. Konstantinides · HI-PEITHO lead author · ACC ↗
“The wisdom of applying this approach to patients with less severe intermediate-risk PE remains unclear and will benefit from additional studies.”
Named experts we found publicly on record — a sample, not a representative poll of the field.
Where do you land?
No votes yet — the measured split appears at 10.
Estimated patients affected
75K–120K
Pulmonary embolism is responsible for ≈100,000 deaths each year in the United States.→Most intermediate-risk PE patients will be effectively treated with anticoagulation.
›How this is estimated
Prevalence: Pulmonary embolism is responsible for ≈100,000 deaths each year in the United States. source
Practice gap: Most intermediate-risk PE patients will be effectively treated with anticoagulation. source
prevalence, ±25% band (no practice-gap input)
Some details are pending source verification and are withheld until confirmed.
“The vast majority of patients with ASCVD worldwide are being managed without knowledge of their Lp(a) levels even though over a quarter are at heightened risk because of their Lp(a). These findings underscore the need for major global educational efforts to promote Lp(a) measurem”
“If elevated Lp(a) levels are detected, they should work closely with their healthcare provider to aggressively lower LDL cholesterol and manage other cardiovascular risk factors as much as possible. This knowledge is especially valuable as new targeted treatment options are on th”
“elevated Lp(a) is an actionable entity today and failing to measure and respond to it represents a missed opportunity to prevent the first manifestations of life-altering ASCVD.”
“If you don’t measure it, if you don’t know how to treat it. I would argue that if you don’t know about your patients’ Lp(a), you also cannot define your primary prevention strategy.”
Vera A. Bittner · Professor of medicine and section head of General Cardiology · AJMC ↗
“While we don’t yet know if lowering Lp(a) translates to fewer cardiovascular events, we do know that identifying high-risk patients allows us to intervene earlier.”
“Elevated Lp(a) is inherited, causal, common, and meaningfully changes lifetime risk assessment. It can guide treatment intensity, helps identify family members at risk, and may inform trial eligibility.”
Michael D. Shapiro · Preventive cardiologist; 2026 ACC/AHA dyslipidemia guideline writing committee member · Medscape ↗
“we should not wait for lipoprotein(a)-lowering therapies, but rather start measuring now.”
Pia R. Kamstrup · Clinical biochemist and Lp(a) researcher · JACC: Case Reports ↗
“Clinicians must be aware of Lp(a) screening guidelines, recommended treatment options, and emerging pharmacotherapies targeting Lp(a) lowering that may soon be available.”
We can crush Lp(a) levels with new agents, but no trial has yet shown that doing so cuts events — treating before the data risks repeating past lipid surprises where surrogate wins didn't translate.
“There are no approved pharmacological therapies to effectively lower Lp(a) for the more than eight million patients living with cardiovascular disease and elevated levels of Lp(a) worldwide.”
Sotirios Tsimikas · Senior Vice President · Ionis ↗
“Horizon study is a pivotal phase 3 study designed to test the hypothesis that treatment with monthly subcutaneous injection of pelacarsen 80 mg will significantly reduce the risk of major adverse cardiovascular events.”
“There are no trials suggesting that this strategy changes outcomes. It’s fine to consider Lp(a), but it should come with a weaker recommendation such as Class IIb “may be considered.””
John M. Mandrola · Cardiac electrophysiologist · Medscape ↗
Named experts we found publicly on record — a sample, not a representative poll of the field.
If PFA isn't more effective and carries an unsettled stroke signal, there's no reason to abandon a cheaper, well-understood technology with decades of track record.
“PFA is here to stay, but the significant increase in the relative stroke risk with PFA should renew our commitment to rigorous post-market surveillance.”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
“This is the first study to demonstrate that newer generation TAVR valves not only appear durable when compared to surgery but may potentially offer slightly better outcomes in specific parameters such as all-cause mortality or disabling stroke.”
“Finally, in the lifetime management of aortic stenosis, SAVR is seriously considered in patients’ younger years to match procedural risk and advancing age appropriately.”
“When the aortic valve anatomy is favorable for TAVR and transfemoral access is possible, TAVR will result in clinical outcomes comparable to those of SAVR. In contrast, when patients have unfavorable anatomy in the TAVR implantation zone or poor femoral access, SAVR is the treatm”
“Although the 5-year result of this trial provides compelling evidence with no significant negative signal against TAVR in terms of the main clinical outcomes and valve performance, our journey to understanding the lifetime management of aortic stenosis is still at its dawn.”
“With some U.S. states documenting that nearly 50% of patients requiring aortic valve replacement aged <65 years receive TAVR rather than guideline-directed SAVR, a significant public health concern may be looming.”
“Although midterm outcomes of TAVR and SAVR are similar, SAVR offers outstanding long-term durability and survival, whereas long-term outcomes of TAVR remain uncertain.”
Prevalence: Aortic stenosis affects 3% of persons older than 65 years. source
Effect size: Patients with severe aortic stenosis who were treated with either Evolut TAVR or surgery showed comparable rates of all-cause mortality or disabling stroke at 5 years (Evolut TAVR [15.5%] and surgery [16.4%]; p=0.47). source
Practice gap: By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. source
prevalence, ±25% band (no practice-gap input)
Some details are pending source verification and are withheld until confirmed.
“Masri responds by highlighting the MAPLE-HCM trial, in which aficamten, used as first-line monotherapy, outperformed metoprolol in terms of LVOT gradient reduction and symptomatic improvement.”
“As all completed phase 3 trials have included patients with high rates of background medical therapy, it is appropriate for beta-blockers and nondihydropyridine calcium channel blockers to remain first-line treatment for oHCM for the immediate future.”
“Two key phase 3 trials, ODYSSEY-HCM and MAPLE-HCM may transform hypertrophic cardiomyopathy care by establishing oral myosin inhibitors... as effective alternatives to invasive strategies.”
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
Raffaele Piccolo · Interventional cardiologist · PCRonline ↗
“OPTIMA-AF trial: In AF patients undergoing PCI with EES, 1-month therapy with DOAC + P2Y12 inhibitor was non-inferior for preventing ischemia and superior for reducing bleeding.”
“OPTIMA-AF provides the first randomised evidence directly addressing conversion to DOAC monotherapy after only 1 month of dual antithrombotic therapy in patients with atrial fibrillation undergoing PCI.”
Ester Sofia Congedo · Interventional cardiologist · PCRonline ↗
“nicely illustrates that less is more, especially in regard to the beneficial effect of less bleeding without an increase in thromboembolism by shortening the use of dual therapy.”
“In patients with AF & chronic coronary syndrome undergoing PCI with IVUS, 1-month dual antithrombotic therapy followed by DOAC monotherapy was non-inferior to 12-month therapy for death or thromboembolic events & reduced major/clinically relevant non-major bleeding at 12 months”
The trial's reassurance came in selected patients on modern stents, and the sickest AF-plus-PCI patients — recent ACS, complex anatomy — may still need the longer antiplatelet cover the wider data can't yet rule out.
Undecided
“in elective PCI patients, now we have some information on potentially stopping the P2Y12 inhibitor sooner... Sometime between 1 and 3 months could be appropriate depending on the patient’s overall ischemic and bleeding risks.”
2 studies (280,876 patients) provide low-certainty evidence for benefit of direct oral anticoagulants for the outcome in stable coronary artery disease.
Supporting
+Multilevel Stewardship Intervention for Use of Anticoagulation-Antiplatelet Therapy
Dissenting
−Predictors of bleeding in patients receiving direct oral anticoagulants
A shorter duration of dual-antiplatelet therapy for percutaneous coronary intervention following acute coronary syndrome: a meta-analysis of randomized clinical trials